Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Enrollment begins in phase II Xcytrin study for metastatic renal cell carcinoma

July 13, 2004

Abbott plans Xinlay NDA filing later this year

July 13, 2004

Antagonists of antiapoptotic protein for the treatment of cancer

July 12, 2004

Bayer describes agents for hyperproliferative disorders

July 12, 2004

Silicon compounds for GnRH related disorders

July 12, 2004

Lorus expands Canadian prostate cancer study of GTI-2501 and docetaxel

July 12, 2004

Enrollment open at European sites in CoFactor phase II study

July 12, 2004

Allergan files INDs for PEP-005 Topical

July 12, 2004

First clinical evidence of antitumor effects induced by taurolidine in glioblastoma

July 9, 2004

ArQule describes lapachone analogues

July 9, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...